Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Coats disease (CD) is an idiopathic disorder characterized by retinal telangiectasia with deposition of intraretinal or subretinal exudates, potentially leading to retinal detachment and unilateral blindness. CD is classically an isolated and unilateral condition affecting otherwise healthy young children.
Features include: Exudative retinal detachment, Retinal telangiectasia, and Leukocoria.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 2 | Exudative retinal detachment, Retinal telangiectasia |
Skin |
An NDP-related retinopathy should be suspected in a male infant with the following ocular findings and family history. Ocular findings. The following spectrum of typically bilateral and symmetric fibrovascular changes of the retina are evident at birth and usually progress through childhood or adolescence to cause varying degrees of visual impairment:
• Norrie disease
Source: GeneReviews — "NDP-Related Retinopathies"
No approved treatments are currently available for Coats disease. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for Coats disease, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for Coats disease. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
Table 6. Recommended Surveillance for Individuals with NDP-Related Retinopathies
System/Concern |
|---|
1 clinical trial registered, 1 recruiting. Interventions under study include medical devices. Pipeline includes 1 PHASE4. Research is primarily sponsored by academic and government institutions.
85 publications have been identified in PubMed for Coats disease. Research spans Case Report / Case Series (35%), Review / Meta-Analysis (31%), and Epidemiology / Natural History (15%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 30 | 35% |
Data assembled from 8 of 12 sources · Last updated Sep 18, 2026, 5:06 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Coats disease
1
Retinal telangiectasia |
NDP-related ocular phenotypes typically involve bilateral and symmetric fibrovascular changes of the retina that are evident at birth and usually progress through childhood or adolescence to cause varying degrees of visual impairment. The NDP-related ocular phenotypes appear to be a continuum with considerable overlap: Norrie disease, NDP-related persistent fetal vasculature (PFV), NDP-related familial exudative vitreoretinopathy (FEVR), NDP-related advanced retinopathy of prematurity (ROP), and NDP-related Coats disease. Table 2. NDP-Related Retinopathies: Ocular Phenotypes
Phenotype | Ocular Findings / Age | Progression / Age | Vision |
|---|---|---|---|
Norrie disease | Grayish-yellow fibrovascular masses of immature retinal cells ("pseudoglioma") behind lens (i.e., retrolental), bilateral total retinal detachments (frequent)/0-3 mos | Cataract, posterior synechiae (iris-to-lens adhesions), anterior synechiae (iris-to-cornea adhesions), iris atrophy, shallowing of anterior chamber, corneal opacification, band keratopathy, shrinking of globe secondary to loss of intraocular pressure (phthisis bulbi)/3 mos to 8-10 yrs | Severely impaired or absent light perception |
NDP-related PFV1 | Fibrotic white stalk w/hyaloid vessel remnants extending from optic disc to posterior lens capsule (unilateral or bilateral)/Birth | Cataract, growth restriction of globe, vitreoretinal traction, retinal exudation, retinal detachment, secondary glaucoma, phthisis bulbi | Varying impairment; amblyopia common if left untreated |
NDP-related FEVR2 | Peripheral retinal avascularity ± congenital retinal folds, temporal macular dragging, fibrovascular scarring at ora serrata/Birth | Retinal ischemia neovascularization, retinal detachment (tractional /or exudative; may be unilateral), subretinal exudation or hemorrhage/≤20 yrs | Mild-to-severe impairment |
NDP-related advanced ROP3 | Retinal neovascularization, extraretinal fibrovascular proliferation, end-stage retrolental fibroplasia, vitreoretinal traction/Premature birth | Partial (Stage 4) or complete (Stage 5) retinal detachment | Mildly impaired-to-absent light perception |
NDP-related Coats disease4 | Unilateral retinal telangiectasia, exudation | Progressive vascular leakage, subretinal exudation fibrosis, retinal detachment (often exudative) | Normal to impaired FEVR = familial exudative vitreoretinopathy; PFV = persistent fetal vasculature; ROP = retinopathy of prematurity 1. 2. NDP pathogenic variants are commonly identified in clinically diagnosed X-linked familial exudative vitreoretinopathy . |
Source: GeneReviews — "NDP-Related Retinopathies"
Table 3. Genes of Interest in the Differential Diagnosis of NDP-Related Retinopathies
Gene(s) | Disorder | MOI | Overlapping Clinical Feature(s) | Comment |
|---|---|---|---|---|
ATOH7 | Autosomal recessive PFV (OMIM 221900) | AR | PFV | To be considered in diffdx of PFV |
CAPN5 | Autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV) (OMIM 193235) | AD | Cataract, synechiae, retinal neovascularization, vitreoretinal traction, fibrovascular proliferation, vitreous hemorrhage, tractional retinal detachment, phthisis, loss of light perception in late stages | Significant uveitis is a hallmark finding in ADNIV (not seen in ND). There are no findings at birth in ADNIV: early signs can be detected in adolescents, but most persons w/ADNIV present as adults. |
CTNNB1 | CTNNB1-related neurodevelopmental disorder (NDD)1 | AD | Assoc w/exudative vitreoretinopathy in some persons | CTNNB1-related NDD is assoc w/mild-to-profound cognitive impairment in all persons. Other common findings: truncal hypotonia, peripheral spasticity, dystonia, behavioral issues, microcephaly, refractive errors strabismus. CTNNB1 FZD4 LRP5 TSPAN12 |
ZNF408 | Nonsyndromic FEVR (OMIM PS133780) | ADAR2 | FEVR, retinal detachment, retinal vascular abnormalities | Genes should be incl in targeted panel for FEVR. |
KIF11 | Microcephaly-lymphedema-chorioretinopathy (OMIM 152950) | AD | FEVR | KIF11 pathogenic variants can cause nonsyndromic ocular findings or be assoc w/microcephaly, peripheral lymphedema, DD, brain anomalies. |
LRP5 | Osteoporosis pseudoglioma syndrome (OMIM 259770) | AR | Pseudoglioma, FEVR; common to have severe exudative vitreoretinopathy congenital blindness | Low bone density fractures are not typical in ND. |
RB1 | Retinoblastoma (RB) | AD | Leukocoria, pseudoglioma, cataract, strabismus | RB must be considered in diffdx of ND, esp in setting of unilateral pseudoglioma. Fundoscopic exam by retina specialist /or ocular oncologist can distinguish between RB ND. Ultrasonography head CT imaging show highly reflective foci in RB, consistent w/calcium deposits. |
Source: GeneReviews — "NDP-Related Retinopathies"
Biomarker and diagnostic research for Coats disease has been reported in the published literature.
Designated
Exclusivity End |
|---|
Designation Status |
|---|
faricimab | faricimab | Genentech, Inc. | 2025 | — | Designated |
No clinical practice guidelines for NDP-related retinopathies have been published.
To establish the extent of disease and needs in an individual diagnosed with an NDP-related retinopathy, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 4.
Recommended Evaluations Following Initial Diagnosis in Individuals with NDP-Related Retinopathies
System/Concern | Evaluation | Comment
| Height, weight, head circumference | Perform at time of clinic eval.
Ophthalmologic
involvement | By pediatric ophthalmologist | Assess best corrected visual acuity, abnormal ocular movement alignment (strabismus), intraocular pressure, refractive error.
By retina specialist /or ophthalmic geneticist | Usually referred by pediatric ophthalmologist if concern for retinal pathology on initial eye exam:
Perform ultrasonography to identify retinal detachment when media opacities are present.
Perform fluorescein angiography of fundus to identify areas of avascularity /or vascular abnormalities.
Assess need for intervention (e.g., surgery, laser, intravitreal injection).
Need for early educational intervention for low vision /or low vision clinic | Refer to early intervention low vision services in infancy, esp when visual impairment is severe.
| Neurologic eval | • Brain MRI
Consider EEG if seizures are a concern.
| Developmental assessment | • Motor, adaptive, cognitive, speec...
Source: GeneReviews — "NDP-Related Retinopathies"
Given the risk of hearing loss, the following are recommended:
Avoidance of exposure to loud noises
Use of hearing protection in noisy environments or when using noisy equipment
Minimal use of ear buds and other listening devices
Source: GeneReviews — "NDP-Related Retinopathies"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "NDP-Related Retinopathies"
1 trial found
Evaluation
Frequency |
|---|
involvement | Visual acuity, ocular alignment, measurement of intraocular pressure refractive error, dilated fundus exam | In infancy: 1x/mo per treating ophthalmologist (as frequency may be 1 or 2x/wk if concerns about imminent progression) |
Seizures | Assess response to medications /or changes in seizure type. | At each visit per family concerns |
Development | Monitor developmental progress educational needs. | At each visit Psychiatric/ |
Behavioral | Behavioral assessment for evidence of ASD, anxiety, ADHD, /or depression | At each visit per family concerns Musculoskeletal/ |
ADL | Physical medicine, OT/PT assessment of mobility, self-help skills | At each visit Sensorineural |
hearing loss | Audiogram incl assessment of speech discrimination | For those w/known hearing loss: per treating audiologist; For those w/o known hearing loss: prior to onset of language, frequent eval; thereafter, every 6 mos Peripheral |
vascular disease | Eval by primary care provider | Annually after age 16 yrs Erectile |
dysfunction | By patient history | At each visit Family/ |
Source: GeneReviews — "NDP-Related Retinopathies"
Estimated prevalence: Unknown (Unknown prevalence).
Research summaries |
26 |
31% |
Disease patterns and progression | 13 | 15% |
Clinical study results | 8 | 9% |
Testing and diagnosis research | 5 | 6% |
Other research | 1 | 1% |
Laboratory research | 1 | 1% |
New treatment approaches | 1 | 1% |
Gui C (2026). [PMID: 41997554](https://pubmed.ncbi.nlm.nih.gov/41997554/). *Photodiagnosis Photodyn Ther*. [Case Report / Case Series]
Park HY (2026). [PMID: 41952137](https://pubmed.ncbi.nlm.nih.gov/41952137/). *BMC Ophthalmol*. [Case Report / Case Series]
Mahesh M (2026). [PMID: 41110679](https://pubmed.ncbi.nlm.nih.gov/41110679/). *Am J Ophthalmol*. [Review / Meta-Analysis]
Motoki A (2026). [PMID: 41551199](https://pubmed.ncbi.nlm.nih.gov/41551199/). *Case Rep Ophthalmol*. [Case Report / Case Series]
Burt SS (2026). [PMID: 39752583](https://pubmed.ncbi.nlm.nih.gov/39752583/). *Retin Cases Brief Rep*. [Case Report / Case Series]
Sharma A (2026). [PMID: 41837574](https://pubmed.ncbi.nlm.nih.gov/41837574/). *Invest Ophthalmol Vis Sci*. [Review / Meta-Analysis]
Slaninová T (2026). [PMID: 41996230](https://pubmed.ncbi.nlm.nih.gov/41996230/). *Cesk Slov Oftalmol*. [Case Report / Case Series]
Singh S (2026). [PMID: 42060352](https://pubmed.ncbi.nlm.nih.gov/42060352/). *Indian J Ophthalmol*. [Review / Meta-Analysis]
Brockmann C (2026). [PMID: 40616365](https://pubmed.ncbi.nlm.nih.gov/40616365/). *Acta Ophthalmol*. [Clinical Trial Publication]
Zeng Q (2026). [PMID: 42135658](https://pubmed.ncbi.nlm.nih.gov/42135658/). *BMC Ophthalmol*. [Case Report / Case Series]